REG - Diaceutics PLC - Results of Annual General Meeting

DiaceuticsAnnouncement

18/05/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230518:nRSR9077Za&default-theme=true

RNS Number : 9077Z  Diaceutics PLC  18 May 2023

18 May 2023

Diaceutics PLC

("Diaceutics" or "the Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the
pharmaceutical industry, is pleased to announce that all resolutions proposed
at its Annual General Meeting held earlier today, were duly passed.

The proxy votes received from shareholders in respect of each resolution are
set out below and are available on the Company's website www.diaceutics.com

 

 Resolution                                                                            For (excluding at Chair's discretion)     Against                  Total votes cast  Withheld
                                                                                       Number of votes      %*                   Number of votes  %*                        Number of votes
 1       Ordinary resolution to receive and consider the 2022 Financial Statements     60,055,552           100.00%              0                0.00%   60,055,552

                                                                                                                                                                            Nil

 2       Ordinary resolution to approve the directors' remuneration report             51,885,466           89.43%               6,131,086        10.57%  60,055,552

                                                                                                                                                                            2,039,000
 3       Ordinary resolution to re-elect Peter Keeling as a director                   59,406,925           98.92%               648,627          1.08%   60,055,552        Nil
 4       Ordinary resolution to re-elect Michael Wort as a director                    55,788,593           92.89%               4,266,959        7.11%   60,055,552        Nil
 5       Ordinary resolution to re-appoint Ernst & Young as auditors                   60,055,552           100.00%              0                0.00%   60,055,552

                                                                                                                                                                            Nil
 6       Ordinary resolution to authorise the directors to determine the remuneration                       100.00%              0                0.00%   60,055,552
         of the auditors

                                                                                                                                                                            Nil

                                                                                       60,055,552
 7       Ordinary resolution to authorise the directors to allot shares                                     100.00%              0                0.00%   60,055,552

                                                                                       60,055,552                                                                           Nil

 8       Special resolution to authorise the directors to disapply pre-emption rights                       99.9%                350              0.01%   60,055,552

                                                                                       60,055,202                                                                           Nil
 9       Special resolution to authorise the directors to purchase own shares          59,976,122           100.00%              0                0.00%   60,055,552

                                                                                                                                                                            79,430

 

*Percentage of votes cast excludes withheld votes

 

Enquiries:

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer                         Via Alma PR
 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)                Tel: +44 (0)20 7710 7600
 Ben Maddison, Nick Harland, Nick Adams

 Alma PR                                                        Tel: +44(0)20 3405 0205
 Caroline Forde, Kieran Breheny, Matthew Young, Kinvara Verdon  diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharmaceutical and life
science companies with solutions and technology for the commercialisation of
their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, utilising a global network of affiliate laboratories to deliver
multiple pipelines of real‐world healthcare data insights, advisory services
and innovative platform enabled solutions.

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGGPURWAUPWGUR